MoonLake Immunotherapeutics - Class A — Quarterly Financial Data (NASDAQ:MLTX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Dividends per share —————— — Dividend yield % —————— — Payout ratio % —————— —

News

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake stock surges on positive axSpA trial data

MoonLake stock surges 63% after InvestingPro Fair Value call

MoonLake reports positive phase 2 axial spondyloarthritis data

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer

BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data

H.C. Wainwright reiterates Buy rating on Moonlake stock with $32 target

MoonLake stock surges after FDA grants Fast Track designation for PPP treatment

FDA grants fast track designation for sonelokimab in PPP

Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns